BioMarin Pharmaceutical Inc. (BMRN) said that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application (sBLA) for BRINEURA (cerliponase alfa) to slow the loss of ambulation in children of all ages with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Previously, BRINEURA was indicated in symptomatic children 3 years of age and older with late infantile CLN2 disease.
The expanded indication now includes children of all ages with CLN2 disease, regardless of whether they are symptomatic or presymptomatic.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.